Skip to main content

IDWeek 2022 Main banner

Tweets by IDWeek 2022

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

385 Views

ViewAttendees 8

Session: Antimicrobial Clinical Trials (Bacterial & Viral)

732 - Microbiologic and clinical outcome concordance in the global phase 3 ATTACK trial: Sulbactam-durlobactam (SUL-DUR) versus colistin therapy in patients with Acinetobacter baumannii-calcoaceticus complex (ABC) infections

Thursday, October 20, 2022

2:15 PM – 2:30 PM US ET

Location: 144 ABC

Watch the live stream on the conference website.

All relevant financial disclosures have been mitigated.

Presenting Author(s)

David Altarac, MD, MPA

Chief Medical Officer
Entasis Therapeutics
Waltham, MA, United States

Disclosure: Disclosure(s): Entasis Therapeutics: Ownership Interest (), Stocks/Bonds ()

Co-Author(s)

Alita Miller, PhD

CSO
Entasis Therapeutics
Waltham, Massachusetts, United States

Disclosure: Disclosure(s): Entasis Therapeutics: Employee ()
Sarah McLeod, PhD (she/her/hers)

Director
Entasis Therapeutics
Waltham, Massachusetts, United States

Disclosure: Disclosure(s): Entasis Therapeutics: Employee ()
AS

Adam B. Shapiro, Ph.D

Research Fellow
Entasis Therapeutics
Waltham, Massachusetts, United States

Disclosure: Disclosure(s): Entasis Therapeutics: Employee (), Stocks/Bonds ()
Khurram Rana, PharmD

Director, Clinical Scientist
Entasis Therapeutics
Waltham, Massachusetts, United States

Disclosure: Disclosure(s): Entasis Therapeutics: Employee (), Ownership Interest (), Stocks/Bonds ()
DL

Drew Lewis, MD, MTM&H

Vice President, Clinical Development
Entasis Therapeutics
Waltham, Massachusetts, United States

Disclosure: Disclosure(s): Entasis Therapeutics: employee (), employee (), Stocks/Bonds (), Stocks/Bonds ()
GP

Gabrielle Poirier, BS

Entasis Therapeutics
Waltham, Massachusetts, United States

Disclosure: Disclosure(s): Entasis Therapeutics: Ownership Interest (), Stocks/Bonds ()
DC

Daria Chabas, BS

Entasis Therapeutics
Waltham, Massachusetts, United States

Disclosure: Disclosure(s): Entasis Therapeutics: Ownership Interest (), Stocks/Bonds ()

Disclosure(s):

David Altarac, MD, MPA: Entasis Therapeutics: Ownership Interest (), Stocks/Bonds ()

Alita Miller, PhD: Entasis Therapeutics: Employee ()

Sarah McLeod, PhD: Entasis Therapeutics: Employee ()

Adam B. Shapiro, Ph.D: Entasis Therapeutics: Employee (), Stocks/Bonds ()

Khurram Rana, PharmD: Entasis Therapeutics: Employee (), Ownership Interest (), Stocks/Bonds ()

Drew Lewis, MD, MTM&H: Entasis Therapeutics: employee (), employee (), Stocks/Bonds (), Stocks/Bonds ()

Gabrielle Poirier, BS: Entasis Therapeutics: Ownership Interest (), Stocks/Bonds ()

Daria Chabas, BS: Entasis Therapeutics: Ownership Interest (), Stocks/Bonds ()